Cryptosporidiosis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Cryptosporidiosis - Pipeline Review, H1 2016', provides an overview of the Cryptosporidiosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cryptosporidiosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cryptosporidiosis - The report reviews pipeline therapeutics for Cryptosporidiosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cryptosporidiosis therapeutics and enlists all their major and minor projects - The report assesses Cryptosporidiosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cryptosporidiosis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cryptosporidiosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cryptosporidiosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Cryptosporidiosis Overview 5 Therapeutics Development 6 Pipeline Products for Cryptosporidiosis - Overview 6 Pipeline Products for Cryptosporidiosis - Comparative Analysis 7 Cryptosporidiosis - Therapeutics under Development by Companies 8 Cryptosporidiosis - Therapeutics under Investigation by Universities/Institutes 9 Cryptosporidiosis - Pipeline Products Glance 10 Early Stage Products 10 Cryptosporidiosis - Products under Development by Companies 11 Cryptosporidiosis - Products under Investigation by Universities/Institutes 12 Cryptosporidiosis - Companies Involved in Therapeutics Development 13 Dafra Pharma International Ltd. 13 ioGenetics, Inc. 14 Romark Laboratories, L.C. 15 Cryptosporidiosis - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Cryptosporidiosis - Dormant Projects 25 Cryptosporidiosis - Discontinued Products 26 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 27 Disclaimer 28
List of Tables
Number of Products under Development for Cryptosporidiosis, H1 2016 6 Number of Products under Development for Cryptosporidiosis - Comparative Analysis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Number of Products under Investigation by Universities/Institutes, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Products under Investigation by Universities/Institutes, H1 2016 12 Cryptosporidiosis - Pipeline by Dafra Pharma International Ltd., H1 2016 13 Cryptosporidiosis - Pipeline by ioGenetics, Inc., H1 2016 14 Cryptosporidiosis - Pipeline by Romark Laboratories, L.C., H1 2016 15 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Cryptosporidiosis - Dormant Projects, H1 2016 25 Cryptosporidiosis - Discontinued Products, H1 2016 26
List of Figures
Number of Products under Development for Cryptosporidiosis, H1 2016 6 Number of Products under Development for Cryptosporidiosis - Comparative Analysis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Number of Products under Investigation by Universities/Institutes, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Targets, H1 2016 17 Number of Products by Stage and Targets, H1 2016 17 Number of Products by Mechanism of Actions, H1 2016 19 Number of Products by Stage and Mechanism of Actions, H1 2016 19 Number of Products by Routes of Administration, H1 2016 21 Number of Products by Stage and Routes of Administration, H1 2016 21 Number of Products by Molecule Types, H1 2016 23 Number of Products by Stage and Top 10 Molecule Types, H1 2016 23
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certainRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.